Keep reading to learn more about GLP-1s and how they work
As such, Rybelsus is not suitable for people with type 1 diabetes due to the increased risk of hypoglycaemia associated with this delayed gastric emptying
10.1111/j.1463-1326.2009.01124.x 93
This is an enormous addressable patient population that has either never started injectable therapy or discontinued it
The data was solid and the weight loss seen in the trials was far superior to the FDA-approved weight loss medications on the market at that time
Andreozzi F, Raciti GA, Nigro C, Mannino GC, Procopio T, Davalli AM, Beguinot F, Sesti G, Miele C, Folli F